ADVANCED MEDICAL SOLUTIONS GROUP PLC

Director's Dealing • Oct 11, 2024

National Storage Mechanism | Additional information

RNS Number : 7813H

Advanced Medical Solutions Grp PLC

11 October 2024

	11 October 2024

Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

Director/PDMR Shareholding

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies , announces th at it was notified on 10 October 2024 that on the same day Grahame Cook, Non-Executive Director, purchased 48,864 ordinary shares of 5p each ("Ordinary Shares") at a price of 205.25p per Ordinary Share.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.

Details of the person discharging managerial responsibilities/person closely associated

a)

Name: Grahame Cook

2.

Reason for the notification

a)

Position/status: Non-Executive Director

b)

Initial notification/Amendment: Initial Notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:   Advanced Medical Solutions Group plc

b)

LEI: 213800HJP6OWOSZI1L74

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument: Ordinary Shares of 5p

Identification code: GB0004536594

b)

Nature of the transactions:

·      Purchase of Ordinary Shares

c)

Price(s) and volume(s):

Price(s)	Volume(s)
Purchase of shares at 205.25p per share	48,864

d)

Aggregated information:

N/A

e)

Date of the transaction: 10/10/2024

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

- End -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: +44 (0) 1606 545508
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations
ICR Consilium	Tel: +44 (0) 20 3709 5700
Mary-Jane Elliott / Lucy Featherstone	AMS@consilium-comms.com
Investec Bank PLC (NOMAD & Broker)	Tel: +44 (0) 20 7597 5970
Gary Clarence / David Anderson
HSBC Bank plc (Broker)	Tel: 44 (0) 20 7991 8888
Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made seven acquisitions: Sealantis, an Israeli developer of innovative internal sealants, Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business, Connexicon, an Irish tissue adhesives specialist, Syntacoll, a German specialist in collagen-based absorbable surgical implants and Peters Surgical, a global provider of specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate devices .

AMS's products, manufactured in the UK, Germany, France, the Netherlands, Thailand, India, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, France, Poland, Benelux, India, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 1,500 employees. For more information, please see www.admedsol.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBLBDGIUBDGSG